Cas:33806-58-5 dihydro-3-(tetradecenyl)-2,5-Furandione manufacturer & supplier

We serve Chemical Name:dihydro-3-(tetradecenyl)-2,5-Furandione CAS:33806-58-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

dihydro-3-(tetradecenyl)-2,5-Furandione

Chemical Name:dihydro-3-(tetradecenyl)-2,5-Furandione
CAS.NO:33806-58-5
Synonyms:EINECS 251-682-3;N-TETRADECENYLSUCCINIC ANHYDRIDE;TDSA;1-Tetradecenylsuccinicanhydride;Tetradecenylsuccinic Anhydride
Molecular Formula:C18H30O3
Molecular Weight:294.42900
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:413.1ºC at 760mmHg
Density:0.97g/cm3
Index of Refraction:1.511
PSA:43.37000
Exact Mass:294.21900
LogP:4.94330

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like EINECS 251-682-3 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Tetradecenylsuccinic Anhydride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-TETRADECENYLSUCCINIC ANHYDRIDE Use and application,TDSA technical grade,usp/ep/jp grade.


Related News: Dr. Elsie Melsopp, Head of Solids Formulations for Alcami, says the company successfully helped a client overcome an API supply shortage using Quality by Design (QbD) studies to successfully formulate an orphan drug product. 5,11,17,23-tetra-[(diethylphosphono)methyl]-25,27-bis(6-methyleneoxy-6′-methyl-2,2′-bipyridyl)-26,28-dihydroxycalix[4]arene manufacturers This scheme has a total outlay of Rs. 6,940 crore for the entire period. The applications under four different target segments were invited on November 30, 2020. Of the 215 applications, 36 products across the 4 target segments were granted. 2-benzenesulfonyl-1,4-bis-[5-(1,5-dimethyl-1-trimethylsilanyloxy-hex-4-enyl)-2-methyl-tetrahydro-furan-2-yl]-4-(4-methoxy-benzyloxy)-butan-1-one suppliers The most frequently reported adverse events for anifrolumab in the TULIP-1 and TULIP-2 trials were upper respiratory tract infection, bronchitis, infusion-related reactions and herpes zoster. 2-cis-4-dichloro-2,4,6,6-tetrakis(dimethylamino)cyclotriphosphazene vendor & factory.